Generic OXYCODONE INN entry, pharmaceutical patent expiry and freedom to operate

Sponsor	Phase
Christopher D. Verrico	PHASE1
Baylor College of Medicine	PHASE1
Region Skane	PHASE4

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XTAMPZA ER	Extended-release Capsules	oxycodone	9 mg, 13.5 mg, 18 mg, 27 mg and 36 mg	208090	1	2017-11-15

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lannett Co Inc	OXYCODONE HYDROCHLORIDE	oxycodone hydrochloride	CAPSULE;ORAL	203823-001	Aug 1, 2014		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Purdue Pharma Lp	OXYCONTIN	oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022272-005	Apr 5, 2010		RX	Yes	Yes	12,246,094	⤷ Start Trial	Y			⤷ Start Trial
Protega Pharms	ROXYBOND	oxycodone hydrochloride	TABLET;ORAL	209777-001	Apr 20, 2017		RX	No	No	7,955,619	⤷ Start Trial	Y			⤷ Start Trial
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-003	Apr 26, 2016		RX	Yes	No	9,968,598	⤷ Start Trial	Y			⤷ Start Trial
Purdue Pharma Lp	OXYCONTIN	oxycodone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022272-002	Apr 5, 2010		RX	Yes	No	9,770,416	⤷ Start Trial	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-002	Apr 26, 2016	9,044,398	⤷ Start Trial
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-002	Apr 26, 2016	8,557,291	⤷ Start Trial
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-003	Apr 26, 2016	10,525,052	⤷ Start Trial
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-003	Apr 26, 2016	8,758,813	⤷ Start Trial
Collegium Pharm Inc	XTAMPZA ER	oxycodone	CAPSULE, EXTENDED RELEASE;ORAL	208090-003	Apr 26, 2016	9,248,195	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
Spain	2653568		⤷ Start Trial
Japan	2017101075	オピオイドおよび他の薬物に関する乱用抑止性の薬学的組成物 (ABUSE-DETERRENT PHARMACEUTICAL COMPOSITIONS OF OPIOIDS AND OTHER DRUGS)	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2005123039		⤷ Start Trial
Japan	2009298822		⤷ Start Trial
Japan	2006500426		⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1685839	92292	Luxembourg	⤷ Start Trial	PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Last updated: February 19, 2026

Oxycodone's market trajectory is defined by declining generic competition, increased regulatory scrutiny, and a shifting landscape of pain management treatments. While historical sales were significant, future revenue streams are impacted by patent expirations, market exclusivity losses, and the ongoing opioid crisis.

What is the Current Market Size for Oxycodone?

The global market for oxycodone, encompassing both branded and generic formulations, has experienced a contraction in recent years. Precise, up-to-the-minute market size figures are proprietary and fluctuate based on data aggregation methodologies. However, industry reports indicate a market that was once valued in the billions of U.S. dollars, now facing pressures that have reduced overall revenue. For instance, in 2022, the U.S. market for prescription opioids, which oxycodone is a significant component of, continued its downward trend from peak values [1]. This decline is attributed to a confluence of factors including reduced prescribing rates, increased patient access to alternative therapies, and the expiration of key patents on branded oxycodone products, leading to widespread generic availability.

Historical Sales Performance

Purdue Pharma's OxyContin, the most prominent branded oxycodone product, achieved peak annual sales exceeding $3 billion in the mid-2000s [2]. This figure underscores the substantial historical financial performance of oxycodone as a pain management solution. However, this performance was followed by extensive litigation and regulatory actions that have fundamentally altered the market.

Factors Influencing Current Market Size

Generic Erosion: Following the expiration of patents for major branded oxycodone products, generic manufacturers entered the market, driving down prices and reducing the revenue share of original innovators.
Regulatory Interventions: Increased governmental oversight and stricter prescribing guidelines in response to the opioid crisis have curtailed the volume of oxycodone dispensed.
Alternative Pain Management: The development and adoption of non-opioid pain management strategies, including non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and interventional therapies, have reduced reliance on oxycodone for certain pain conditions.

What is the Patent Landscape for Oxycodone?

The patent landscape for oxycodone is characterized by the expiration of foundational patents for its original formulations and the ongoing development of new delivery systems and combination therapies.

Key Patent Expirations

The primary patents for immediate-release and extended-release oxycodone formulations have long since expired. For example, the patent for Purdue Pharma's original OxyContin formulation expired in the early 2000s, paving the way for generic competition [3]. Subsequent patents related to specific formulations, such as abuse-deterrent technologies, have also faced challenges and expirations.

Current Patent Activity

While patents on basic oxycodone molecules are expired, current patent activity focuses on:

Abuse-Deterrent Formulations (ADFs): Innovations aimed at making oxycodone harder to crush, dissolve, or inject. While some ADF patents have been litigated and upheld, their market exclusivity is finite.
Combination Products: Patents protecting oxycodone when combined with other active pharmaceutical ingredients (APIs) for synergistic pain relief or to mitigate specific side effects.
Novel Delivery Systems: Patents covering new methods of administering oxycodone, such as transdermal patches or long-acting injectables, that may offer improved pharmacokinetics or patient compliance.

Impact of Patent Expirations

The widespread expiration of oxycodone patents has resulted in:

Increased Generic Availability: Multiple generic manufacturers now produce oxycodone, leading to intense price competition.
Reduced Profit Margins: Pharmaceutical companies relying on oxycodone sales primarily through generic channels face significantly lower profit margins compared to the era of branded exclusivity.
Litigation Risk: While patents on older formulations are expired, ongoing litigation surrounding marketing practices, opioid crisis liability, and patent challenges to newer formulations continues to impact financial outcomes for companies involved.

What is the Regulatory Environment Surrounding Oxycodone?

The regulatory environment for oxycodone is exceptionally stringent, driven by the ongoing public health crisis associated with opioid addiction and overdose.

U.S. Regulatory Framework

In the United States, the Drug Enforcement Administration (DEA) and the Food and Drug Administration (FDA) are the primary regulatory bodies.

DEA Scheduling: Oxycodone is classified as a Schedule II controlled substance under the Controlled Substances Act [4]. This classification imposes strict controls on manufacturing quotas, prescribing, dispensing, and record-keeping requirements.
FDA Oversight: The FDA regulates the approval, labeling, and post-market surveillance of oxycodone products. This includes requirements for Risk Evaluation and Mitigation Strategies (REMS) for certain opioid medications, designed to ensure that the benefits of these drugs outweigh their risks [5].
State-Level Regulations: Individual states have implemented their own regulations, often more restrictive than federal guidelines, including prescription drug monitoring programs (PDMPs) and limitations on opioid prescription durations.

International Regulatory Trends

Globally, many countries have adopted similar measures to control opioid access and mitigate risks. This includes:

Prescription Requirements: Mandating physician prescriptions for all oxycodone products.
Dispensing Limits: Implementing limits on the quantity of opioids that can be dispensed at one time.
Monitoring Programs: Establishing national or regional databases to track opioid prescriptions and identify potential misuse.

Impact of Regulations on Market Access

These regulations have a direct impact on the market by:

Reducing Prescribing Volume: Stricter guidelines and increased physician awareness have led to a documented decrease in oxycodone prescriptions.
Increasing Compliance Costs: Pharmaceutical manufacturers and distributors face higher operational costs due to stringent tracking, reporting, and security measures.
Limiting Market Growth Potential: The regulatory environment inherently restricts the potential for market expansion and dictates that any growth must be within tightly controlled parameters.

What are the Financial Implications and Investment Outlook for Oxycodone?

The financial implications for companies involved with oxycodone are mixed, characterized by declining revenue from legacy products and significant liabilities from litigation, offset by niche opportunities and the continued demand for pain management solutions.

Revenue Trajectory

Declining Branded Sales: Sales of formerly dominant branded oxycodone products have drastically reduced due to generic competition and market shifts.
Generic Market Dynamics: The generic oxycodone market is highly competitive, with low profit margins per unit. Revenue is largely dependent on volume and efficient manufacturing.
Litigation Costs: Many companies, particularly those historically associated with the marketing of oxycodone, face substantial financial exposure from opioid-related litigation, impacting overall profitability and cash flow. This has led to bankruptcies and significant settlements for companies like Purdue Pharma [2].

Investment Considerations

High Risk for Pure Oxycodone Players: Investments in companies whose primary revenue stream is solely from generic oxycodone face significant risks due to price erosion and limited growth potential.
Diversification is Key: Companies with diversified portfolios that include oxycodone as a smaller component, alongside other therapeutic areas, are better positioned to mitigate risks.
Focus on Innovation: Investment interest may shift towards companies developing next-generation pain management solutions or novel delivery systems for existing analgesics, rather than basic oxycodone formulations.
Liability Mitigation: Potential investors must thoroughly assess the litigation exposure of any company involved in the oxycodone supply chain.

Financial Performance Metrics

Profit Margins: Generic oxycodone manufacturers typically operate on lower profit margins compared to branded pharmaceuticals.
Revenue Volatility: Revenue can be volatile, influenced by regulatory changes, pricing pressures, and the success of generic market entry by competitors.
Market Share: Maintaining or gaining market share in the generic space is crucial for revenue stability, but often comes at the cost of aggressive pricing strategies.

What are the Future Trends and Alternatives in Pain Management?

The future of pain management is moving away from a singular reliance on opioids like oxycodone towards a multi-modal approach that emphasizes non-addictive alternatives and personalized treatment plans.

Non-Opioid Analgesics

NSAIDs and Acetaminophen: These remain first-line treatments for mild to moderate pain. Newer formulations and combination products continue to be developed.
Neuropathic Pain Agents: Medications such as gabapentinoids (e.g., gabapentin, pregabalin) and certain antidepressants (e.g., SNRIs, TCAs) are increasingly used for nerve-related pain.
Topical Agents: Over-the-counter and prescription topical treatments, including lidocaine patches and capsaicin creams, offer localized pain relief with reduced systemic side effects.

Novel Therapies and Technologies

Cannabinoids: Research into the therapeutic potential of cannabinoids for pain management is ongoing, with some formulations gaining traction.
Biologics: For inflammatory pain conditions, biologics targeting specific inflammatory pathways are becoming more prevalent.
Non-Pharmacological Interventions: Physical therapy, cognitive behavioral therapy (CBT), acupuncture, and mindfulness-based stress reduction are increasingly integrated into pain management protocols.
Digital Health Solutions: Wearable devices, AI-driven pain tracking apps, and telehealth platforms are emerging to support patient self-management and remote monitoring.

Impact on Oxycodone Demand

These trends collectively suggest a declining role for oxycodone in general pain management. Its use is expected to become increasingly confined to:

Severe Acute Pain: Short-term use for post-surgical or trauma-related pain where other options are insufficient.
Specific Chronic Pain Conditions: Carefully managed cases of severe chronic pain that are refractory to other treatments, often under strict monitoring.
Palliative Care: Symptom management in end-of-life care.

The market for oxycodone will therefore likely continue to shrink, with revenue driven by generic sales for limited indications and the lingering impact of past market dominance and associated liabilities.

Key Takeaways

Oxycodone's market size has contracted significantly from its peak, primarily due to generic competition and regulatory pressures stemming from the opioid crisis.
The patent landscape for basic oxycodone formulations has expired, with current patent activity focused on abuse-deterrent formulations and combination products.
The regulatory environment is characterized by stringent controls under the DEA and FDA, imposing strict manufacturing, prescribing, and dispensing requirements.
Financial implications for oxycodone are marked by declining revenues from legacy products and substantial litigation liabilities, making investment in pure oxycodone plays high-risk.
Future trends in pain management emphasize non-opioid alternatives, non-pharmacological interventions, and technological advancements, suggesting a continued reduction in oxycodone's market share.

Frequently Asked Questions

1. What is the primary reason for the decline in oxycodone sales?

The primary reasons are the expiration of patents for branded formulations, leading to widespread generic competition and drastic price reductions, coupled with intensified regulatory scrutiny and public health initiatives to combat opioid addiction.

2. How do abuse-deterrent formulations (ADFs) impact the oxycodone market?

ADFs aim to make oxycodone harder to misuse. While they may offer some protection against certain forms of abuse, their market impact is limited by the continued availability of generic immediate-release formulations and ongoing challenges to ADF patent validity.

3. Are there any new branded oxycodone products with significant market potential?

The focus for new product development in pain management has largely shifted away from novel oxycodone formulations towards non-opioid analgesics and alternative therapeutic modalities due to regulatory and market disincentives.

4. What are the major financial risks for companies still involved in the oxycodone market?

Major financial risks include ongoing opioid litigation and potential future settlements, significant price erosion in the generic market, and the high cost of regulatory compliance.

5. How is the opioid crisis impacting the future research and development for pain medications?

The opioid crisis has redirected R&D efforts towards developing non-addictive pain relief options, including novel non-opioid compounds, regenerative medicine, and non-pharmacological approaches, to a greater extent than further innovation in opioid-based therapies.

Citations

[1] National Institute on Drug Abuse. (2023). Opioid Overdose Crisis. Retrieved from https://www.drugabuse.gov/drug-topics/opioids/opioid-overdose-crisis

[2] Harris, B. (2021, September 13). Purdue Pharma, maker of OxyContin, files for bankruptcy for third time. NPR. Retrieved from https://www.npr.org/2021/09/13/1036457288/purdue-pharma-maker-of-oxycontin-files-for-bankruptcy-for-third-time

[3] U.S. Food & Drug Administration. (n.d.). FDA Drug Shortages. Retrieved from https://www.fda.gov/drugs/drug-shortages (Note: While this source doesn't directly cite patent expiry dates, it illustrates ongoing availability of generic forms which implies patent expiry).

[4] U.S. Drug Enforcement Administration. (n.d.). Controlled Substances Act. Retrieved from https://www.dea.gov/drug-scheduling

[5] U.S. Food & Drug Administration. (2020, April 9). Opioid Medications. Retrieved from https://www.fda.gov/drugs/information-drug-class/opioid-medications

International Patents:	24
US Patents:	25
Tradenames:	6
Applicants:	32
NDAs:	53
Drug Master File Entries:	19
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	24
Clinical Trials:	632
Drug Prices:	Drug price trends for oxycodone
Drug Sales Revenues:	Drug sales revenues for oxycodone
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for oxycodone
What excipients (inactive ingredients) are in oxycodone?	oxycodone excipients list
DailyMed Link:	oxycodone at DailyMed

Applicant	Application No.	Strength	Dosage Form
⤷ Start Trial	⤷ Start Trial	80MG	TABLET, EXTENDED RELEASE; ORAL
⤷ Start Trial	⤷ Start Trial	80MG	TABLET, EXTENDED RELEASE; ORAL
⤷ Start Trial	⤷ Start Trial	40MG	TABLET, EXTENDED RELEASE; ORAL

Drug Class	Opioid Agonist
Mechanism of Action	Full Opioid Agonists

Summary for oxycodone

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for oxycodone

Recent Clinical Trials for oxycodone

Generic filers with tentative approvals for OXYCODONE

Pharmacology for oxycodone

Medical Subject Heading (MeSH) Categories for oxycodone

Anatomical Therapeutic Chemical (ATC) Classes for oxycodone

Paragraph IV (Patent) Challenges for OXYCODONE